Filtern
Volltext vorhanden
- ja (31)
Gehört zur Bibliographie
- ja (31)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (31) (entfernen)
Schlagworte
- prostate cancer (6)
- radiotherapy (6)
- DNA damage (3)
- IGRT (3)
- hypofractionation (3)
- long-term outcome (3)
- rectal cancer (3)
- toxicity (3)
- DNA repair (2)
- Glioblastoma (2)
- Halcyon (2)
- cancer (2)
- cone beam CT (2)
- image-guided radiation therapy (2)
- radiosensitivity (2)
- radiotherapy (RT) (2)
- salvage radiotherapy (2)
- simultaneous integrated boost (2)
- 4D-MRI (1)
- ATM (1)
- Adaptation (1)
- Akt (1)
- Brain cancer (1)
- CD133 (1)
- CIED malfunction; pacemaker (PM) (1)
- CNS cancer (1)
- Corticosteroids (1)
- DNA double strand breaks (1)
- DNA repair protraction (1)
- DNA-PK (1)
- DNS-Reparatur (1)
- DNS-Schädigung (1)
- Glioma stem cells (1)
- High grade glioma (1)
- IMRT (1)
- IR (1)
- NSCLC (1)
- NVP-BEZ235 (1)
- Nestin (1)
- Non-rigid image registration (1)
- Novel PI3K (1)
- Osteopontin (1)
- PI3K (1)
- PSMA (1)
- PSMA PET/CT (1)
- PTEN (1)
- Peripheral blood lymphocytes (1)
- Prostate carcinoma (1)
- Radiosensitivity (1)
- Radiotherapy (1)
- Radiotherapy treatment planning (1)
- Respiratory induced tumor motion (1)
- Synergy (1)
- TGFβ1 (1)
- Temozolomide (1)
- VMAT (1)
- \(\gamma\)h2ax (1)
- accelerated hyperfractionation (1)
- acute toxicity (1)
- adaptation (1)
- adaptive radiotherapy (1)
- adrenal tumours (1)
- adrenocortical carcinoma (ACC) (1)
- altered fractionation (1)
- apoptosis (1)
- auto-planning (1)
- autophagy (1)
- battery depletion (1)
- biochemical relapse free survival (1)
- blood lymphocytes (1)
- cardiac implantable electronic devices (CIED) (1)
- cardiac resynchronization therapy (CRT) (1)
- chemoradiotherapy (1)
- deformable image registration (1)
- dominant intraprostatic lesion (1)
- dose accumulation (1)
- dose escalation (1)
- dose evaluation (1)
- dose to OARs (1)
- double arc (1)
- external beam radiotherapy (EBRT) (1)
- foci (1)
- full arc (1)
- glioblastoma (1)
- head and neck cancer (1)
- head and neck squamous cell carcinoma (1)
- high-dose-rate (HDR) brachytherapy (1)
- high-dose-rate brachytherapy boost (1)
- histone H2AX (1)
- hypoxia (1)
- implantable cardioverter defibrillator (ICD) (1)
- in vivo (1)
- individual radiosensitivity (1)
- intensity-modulated radiation therapy (1)
- intensity-modulated radiotherapy (1)
- irradiation (1)
- local control (1)
- lung cancer (1)
- mTOR Inhibitor (1)
- macroscopic recurrence (1)
- megavoltage computed-tomography (1)
- metastasis-directed therapy (1)
- multimodal therapy (1)
- multiple brain metastases (1)
- neck cancer (1)
- neoadjuvant (1)
- oligorecurrence (1)
- oral mucositis (1)
- osteopontin (1)
- outcomes research (1)
- oxidative DNA damage (1)
- partial arc (1)
- perioperative changes (1)
- peripheral blood lymphocytes (1)
- phosphorylation (1)
- plan comparison (1)
- propensity score matching (1)
- prostate Imaging Reporting and Data System (1)
- radiosensibility (1)
- re-irradiation (1)
- re-planning (1)
- repair (1)
- risk (1)
- risk score (1)
- setup verification (1)
- single arc (1)
- strategies (1)
- survival (1)
- temozolomide (1)
- thoracic cancer (1)
- transperineal ultrasound (1)
- treatment plan (1)
- variability (1)
- whole breast irradiation (1)
- zinc oxide nanoparticles (1)
Institut
- Klinik und Poliklinik für Strahlentherapie (30)
- Comprehensive Cancer Center Mainfranken (3)
- Klinik und Poliklinik für Nuklearmedizin (3)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (2)
- Medizinische Klinik und Poliklinik I (2)
- Pathologisches Institut (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Frauenklinik und Poliklinik (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Medizinische Strahlenkunde und Zellforschung (1)
Background: There is a lack of predictive models to identify patients at risk of high neoadjuvant chemoradiotherapy (CRT)-related acute toxicity in rectal cancer. Patient and Methods: The CAO/ARO/AIO-04 trial was divided into a development (n = 831) and a validation (n = 405) cohort. Using a best subset selection approach, predictive models for grade 3–4 acute toxicity were calculated including clinicopathologic characteristics, pretreatment blood parameters, and baseline results of quality-of-life questionnaires and evaluated using the area under the ROC curve. The final model was internally and externally validated. Results: In the development cohort, 155 patients developed grade 3–4 toxicities due to CRT. In the final evaluation, 15 parameters were included in the logistic regression models using best-subset selection. BMI, gender, and emotional functioning remained significant for predicting toxicity, with a discrimination ability adjusted for overfitting of AUC 0.687. The odds of experiencing high-grade toxicity were 3.8 times higher in the intermediate and 6.4 times higher in the high-risk group (p < 0.001). Rates of toxicity (p = 0.001) and low treatment adherence (p = 0.007) remained significantly different in the validation cohort, whereas discrimination ability was not significantly worse (DeLong test 0.09). Conclusion: We developed and validated a predictive model for toxicity using gender, BMI, and emotional functioning. Such a model could help identify patients at risk for treatment-related high-grade toxicity to assist in treatment guidance and patient participation in shared decision making.